Please ensure Javascript is enabled for purposes of website accessibility

Abbott's Implantable Heart Pump System Gets FDA's Breakthrough Device Designation

By Mark Prvulovic - Updated Feb 4, 2020 at 4:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This device, which is still in development, could help hundreds of thousands of Americans if approved.

Abbott Laboratories (ABT 0.90%) announced on Tuesday its in-development implantable heart pump system received the Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Fully Implantable Left Ventricular Assist System (FILVAS) is a device used for patients with advanced heart failure who otherwise would require a heart transplant.

Heart pumps are small devices that pump blood throughout the body similarly to how a regular heart operates. There are more than 6 million Americans that have some form of heart failure, while over 600,000 of them are at a stage where standard treatments, such as medications, are no longer effective. Devices such as Abbott's FILVAS are one possible solution for this group of patients, especially since heart transplants aren't possible for everyone.

Abstract 3d image of a heart and a cardiogram monitoring a heart beat.

Image source: Getty Images.

The current generation of left ventricular assist devices are implanted directly into the body and then require an external battery or a charging port. In comparison, Abbott's FILVAS will not require any external components at all. It's a significant convenience factor for patients, who wouldn't need to carry around external components wherever they go.

Further details

Abbott has been growing its heart pump business segment since acquiring St. Jude Medical and its HeartMate product line in 2017. This includes the FDA-approved HeartMate 3 LVAD (left ventricular assist device), which is used by patients with advanced heart failure who aren't eligible for a heart transplant.

In December, the healthcare giant also announced that the FDA would allow its HeartMate 3 device to be implanted through a new procedure called lateral thoracotomy, which is less invasive than previous implantation methods, allowing patients to avoid open heart surgery.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$111.48 (0.90%) $0.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.